The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Subscribe To Our Newsletter & Stay Updated
